Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emotionally charged FDA memos could mean fireworks at Avandia meeting

This article was originally published in Scrip

Executive Summary

As highly charged meetings go, the two-day gathering on 5-6 June of the FDA's Endocrinologic and Metabolic Drugs (EMDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committees to review the results of a an independent readjudication of GlaxoSmithKline's controversial RECORD study of the firm's Type II diabetes drug Avandia (rosiglitazone) is expected to spark some early 4th of July fireworks, or at least, if the briefing documents are any indicator.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts